CanadaBis CapitalCNADF -89.50% EBITDA Margin % is 10.94% as of Oct. 2025, which is 74% above its 10-year median of 6.29. The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, CanadaBis Capital ranks worse than 70.89% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CanadaBis Capital's EBITDA for the
three
months ended in Oct. 2025 was $0.26 Mil. CanadaBis Capital's Revenue for the
three
months ended in Oct. 2025 was $2.33 Mil. Therefore, CanadaBis Capital's EBITDA margin for the quarter that ended in Oct. 2025 was 10.94%.
CanadaBis Capital (OTCPK:CNADF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CanadaBis Capital EBITDA Margin % Related Terms
CanadaBis Capital EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CanadaBis Capital's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanadaBis Capital EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CanadaBis Capital's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanadaBis Capital (CNADF) has a EBITDA Margin % of 10.94% as of Oct. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CanadaBis Capital and its competitors. This is 74% above median its historical median of 6.29. According to the industry distribution chart, CanadaBis Capital ranks #677 out of 955 companies in the Drug Manufacturers industry, placing it in the top 70.9%.
Is CanadaBis Capital's EBITDA Margin % too high?
CanadaBis Capital's current EBITDA Margin % of 10.94% is 74% above median its 10-year median of 6.29. The Drug Manufacturers industry median EBITDA Margin % is 12.44. CanadaBis Capital's value of 10.94% is 12.1% below this industry median. Based on the distribution chart, CanadaBis Capital ranks #677 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does CanadaBis Capital's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #677 out of 955 companies for EBITDA Margin %. This places CanadaBis Capital in the lower half of its industry. The industry median EBITDA Margin % is 12.44. CanadaBis Capital's value of 10.94% is 12.1% below this benchmark. While the company's 10-year median is 6.29 vs. the industry median of 12.44, CanadaBis Capital has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanadaBis Capital's current EBITDA Margin % of 10.94% is 12.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CanadaBis Capital and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current EBITDA Margin % is 10.94%, which is 74% above median its own 10-year median of 6.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (CNADF) has a current EBITDA Margin % of 10.94%. The current EBITDA Margin % is 10.94%, which is 74% above median its 10-year median of 6.29 and 12.1% below the Drug Manufacturers industry median of 12.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CanadaBis Capital (CNADF), the current EBITDA Margin % is 10.94% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNADF has been successfully added to your 